Alexa B Schrock

List of Publications by Year
in descending order

106 papers	8,290 citations	108046 37 h-index	58552 86 g-index
106 all docs	106 docs citations	106 times ranked	12805 citing authors

#	Article	IF	Citations
1	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clinical Cancer Research, 2022, 28, 728-737.	3.2	20
2	ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Antiâ€“Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. JCO Precision Oncology, 2022, 6, e2100330.	1.5	3
3	Abstract P3-07-02: Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond. Cancer Research, 2022, 82, P3-07-02-P3-07-02.	0.4	0
4	Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). Cancer Research, 2022, 82, PD14-09-PD14-09.	0.4	1
5	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2022, 5, e225394.	2.8	37
6	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	0.8	9
7	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	1.5	2
8	Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers. Oncologist, 2022, 27, 919-929.	1.9	16
9	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precision Oncology, 2022, , .	1.5	10
10	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	1.5	10
11	Clinicopathologic, genomic and protein expression characterization of 356 <scp>ROS1</scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	2.3	14
12	RAS Amplification as a Negative Predictor of Benefit from Anti-EGFRâ€“Containing Therapy Regimens in Metastatic Colorectal Cancer. Oncologist, 2021, 26, 469-475.	1.9	7
13	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	3.2	11
14	Structureâ€“function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications, 2021, 12, 1382.	5.8	34
15	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	13.9	482
16	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. JTO Clinical and Research Reports, 2021, 2, 100194.	0.6	7
17	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	2.0	5
18	Real-world association of HER2/ERBB2concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncology, 2021, 17, 4101-4114.	1.1	7

#	Article	IF	Citations
19	Characterization of Nonâ€“Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precision Oncology, 2021, 5, 1354-1376.	1.5	12
20	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	13.7	185
21	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
22	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Translational Oncology, 2021, 14, 101184.	1.7	13
23	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15.	0.8	7
24	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Antiâ€“PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	1.5	17
25	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist, 2020, 25, e147-e159.	1.9	220
26	The Panâ€€Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
27	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	2.2	27
28	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Oncology, 2020, 98, 905-912.	0.9	27
29	Evidenceâ€Based Development and Clinical Use of Precision Oncology Therapeutics. Clinical Pharmacology and Therapeutics, 2020, 108, 440-443.	2.3	4
30	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. Lung Cancer, 2020, 148, 69-78.	0.9	25
31	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors . Lung Cancer: Targets and Therapy, 2020, Volume 11, 33-39.	1.3	2
32	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. Journal of Thoracic Oncology, 2020, 15, 766-776.	0.5	68
33	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. European Urology, 2020, 77, 548-556.	0.9	41
34	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU International, 2020, 125, 739-746.	1.3	14
35	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. European Urology Focus, 2019, 5, 748-755.	1.6	29
36	FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	1.9	16

#	Article	IF	Citations
37	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. Journal of Gastrointestinal Oncology, 2019, 10, 831-840.	0.6	31
38	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	7.7	145
39	Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib. Journal of Thoracic Oncology, 2019, 14, e27-e29.	0.5	23
40	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. Journal of Thoracic Oncology, 2019, 14, e29-e30.	0.5	4
41	Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. Journal of the American Academy of Dermatology, 2019, 80, 1780-1782.	0.6	7
42	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology, 2019, 156, 2242-2253.e4.	0.6	224
43	Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification . Lung Cancer: Targets and Therapy, 2019, Volume 10, 21-26.	1.3	22
44	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clinical Cancer Research, 2019, 25, 3341-3351.	3.2	80
45	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. Oncologist, 2019, 24, 657-663.	1.9	5
46	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist, 2019, 24, 1340-1347.	1.9	73
47	Atypical RAS Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	1.5	1
48	Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitorâ€“Acquired Resistance in a Microsatellite Instabilityâ€“High Gastroesophageal Adenocarcinoma With Brain Metastases. JCO Precision Oncology, 2019, 3, 1-6.	1.5	3
49	Detection of Known and Novel FGFR Fusions in Nonâ€“Small Cell Lung Cancer by Comprehensive Genomic Profiling. Journal of Thoracic Oncology, 2019, 14, 54-62.	0.5	64
50	Hybrid Captureâ€“Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 255-264.	0.5	53
51	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. Journal of Urology, 2019, 201, 541-548.	0.2	57
52	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 696-713.	7.7	107
53	EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?. Journal of Thoracic Oncology, 2018, 13, e33-e34.	0.5	17
54	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer, 2018, 124, 1358-1373.	2.0	151

#	Article	IF	Citations
55	Hybrid Captureâ€“Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59
56	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist, 2018, 23, 776-781.	1.9	8
57	Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion. Clinical Breast Cancer, 2018, 18, e267-e270.	1.1	18
58	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	1.5	24
59	Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion. JCO Precision Oncology, 2018, 2, 1-6.	1.5	13
60	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of Gastrointestinal Oncology, 2018, 9, 610-617.	0.6	192
61	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	0.8	246
62	RET rearrangements are actionable alterations in breast cancer. Nature Communications, 2018, 9, 4821.	5.8	87
63	Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer: Targets and Therapy, 2018, Volume 9, 111-116.	1.3	6
64	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology, 2018, 13, 1560-1568.	0.5	158
65	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-Î± N848â€‰K mutation. Lung Cancer, 2018, 124, 86-89.	0.9	0
66	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. Lung Cancer: Targets and Therapy, 2018, Volume 9, 45-47.	1.3	10
67	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1312-1323.	0.5	103
68	Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatric Blood and Cancer, 2017, 64, e26433.	0.8	92
69	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR -mutated Lung Adenocarcinoma Reveals an Acquired FGFR3 - TACC3 Fusion. Clinical Lung Cancer, 2017, 18, e219-e222.	1.1	15
70	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 872-877.	0.5	87
71	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	1.1	38
72	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist, 2017, 22, 255-263.	1.9	60

#	Article	IF	Citations
73	CD74 - ROS1 Fusion in NSCLCÂDetected by Hybrid Captureâ€“Based Tissue Genomic Profiling and ctDNA Assays. Journal of Thoracic Oncology, 2017, 12, e19-e20.	0.5	6
74	FRMD4A / RET : A Novel RET Oncogenic Fusion Variant inÂNonâ€“Small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2017, 12, e15-e16.	0.5	21
75	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 2017, 9, 34.	3.6	2,480
76	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e155-e157.	0.5	9
77	Identification of a novel T1151K ALK mutation in a patient with ALK -rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer, 2017, 110, 32-34.	0.9	16
78	Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist, 2017, 22, 774-779.	1.9	16
79	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer, 2017, 108, 228-231.	0.9	125
80	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	183
81	Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncology, 2017, 3, 1546.	3.4	154
82	Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. Oncologist, 2017, 22, 416-421.	1.9	46
83	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Journal of Thoracic Oncology, 2017, 12, 932-942.	0.5	129
84	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. Journal of Thoracic Oncology, 2017, 12, 446-457.	0.5	75
85	Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e211-e213.	1.1	8
86	A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. Pediatric Blood and Cancer, 2017, 64, e26377.	0.8	6
87	ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. Oncologist, 2017, 22, 1444-1450.	1.9	81
88	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. Human Pathology, 2017, 70, 84-91.	1.1	20
89	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer, 2017, 123, 3628-3637.	2.0	57
90	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist, 2017, 22, 1478-1490.	1.9	176

#	Article	IF	Citations
91	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer, 2017, 111, 61-64.	0.9	44
92	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology, 2017, 12, e89-e90.	0.5	34
93	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. BMC Cancer, 2017, 17, 197.	1.1	5
94	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology, 2017, 12, 137-140.	0.5	102
95	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. JCO Precision Oncology, 2017, 1, 1-7.	1.5	3
96	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. JCO Precision Oncology, 2017, 1, 1-6.	1.5	1
97	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Experimental Hematology and Oncology, 2017, 6, 29.	2.0	12
98	Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2â€“Targeted Therapy. JCO Precision Oncology, 2017, 1, 1-9.	1.5	0
99	^{Non-V600}BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 2624-2630.	0.8	267
100	TMPRSS2-ERG Fusions Unexpectedly Identified in Men Initially Diagnosed With Nonprostatic Malignancies. JCO Precision Oncology, 2017, 2017, 1-6.	1.5	10
101	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	2.3	26
102	BRAF V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAFâ€“MEK Combination Therapy. Cancer Discovery, 2016, 6, 594-600.	7.7	75
103	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist, 2016, 21, 1306-1314.	1.9	36
104	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Journal of Thoracic Oncology, 2016, 11, 1493-1502.	0.5	288
105	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer, 2016, 97, 48-50.	0.9	36
106	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Clinical Cancer Research, 2016, 22, 3281-3285.	3.2	33